Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 02 Jul, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
© 2026 by Asian Media Group Inc.
Recent Articles
- Zuckerberg Says Meta AI Agent Tech Progressing Slower Than Expected
- Japan's Services Activity Returned to Growth in June
- Air Force to Investigate Officer Who Called for Trump Impeachment
- How Americans Plan to Celebrate July 4th 250
- Tesla's China-Made EV Sales Jumped 24.4% on Year in June
- OpenAI Proposes AI Firms Hand 5% Stakes to US Government
- Microsoft Launches Firm to Help Companies Adopt AI with $2.5 Billion
- Rivian Raises 2026 Delivery Forecast on Strong Demand, R2 Boost
- US Job Growth Slowed in June but Unemployment Rate Fell to 4.2% As Labor Force Shrinks
- Tesla Posts Record Q2 Deliveries on Europe Sales Rebound